Compare Biogen Inc (BIIB) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Monolithic Power Systems Inc — how do they compare? Biogen Inc trades at $190.45 (market cap $28.34B), while Monolithic Power Systems Inc trades at $1,383.38 (market cap $67.62B). The key difference: Monolithic Power Systems Inc is far larger — about 2.4× Biogen Inc's market cap, and Monolithic Power Systems Inc pays a 0.58% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MPWR | |
|---|---|---|
Market Cap | $28.34B | $67.62B |
Sector | Health | Utilities |
52-Week High | $216.63 | $1.69K |
52-Week Low | $122.68 | $711.24 |
Enterprise Value | $30.62B | $66.28B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Monolithic Power Systems (MPWR) trades at $1,291.38, down 4.54% on the day, amid a bearish technical signal despite strong fundamentals. The stock shows robust profitability with 22.98% net income margin and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains strongly bullish with 88% buy ratings and a $1,760 price target, representing significant upside potential from current levels.
The stock presents a compelling growth opportunity driven by AI infrastructure demand and power semiconductor trends, though elevated valuation multiples and ongoing legal investigations pose risks. Technical indicators suggest near-term weakness, but strong institutional support and consistent earnings performance support the long-term bullish case for investors seeking exposure to semiconductor growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
